Rival Signals and Project Selection: Insights from the Drug Development Process
- 1 September 2023
- journal article
- research article
- Published by Institute for Operations Research and the Management Sciences (INFORMS) in Management Science
- Vol. 69 (9) , 5298-5315
Abstract
Project selection decisions are complex because they must balance not only financial returns, project risk, and fit with strategy, but also competitive circumstances. A rival’s project development efforts provide two pieces of information: a market rivalry signal, indicating potentially heightened competition in a market, and a technological signal, indicating a possible solution to a problem in that market. We hypothesize that these signals affect a firm’s likelihood of project selection in opposite directions, and that the timing of the signals matters for selection. We examine the drug development pipelines of the top 15 pharmaceutical companies from 1999 to 2016 to examine how rival projects drive the decision to progress a drug from preclinical laboratory trials to clinical trials in humans. Early-stage rival projects provide a stronger market rivalry signal, and they are associated with a decreased likelihood of the firm selecting its own project to compete in the same market. Late-stage rival projects signal technological feasibility and are associated with an increase in the likelihood of selection. We then exploit heterogeneity in market potential (i.e., disorder prevalence/incidence) and a molecular compound’s technology (i.e., therapeutic modality) to independently manipulate the salience of the two signals. Finally, we provide evidence on how selection based on rival signals informs project success. Information from rival projects prompts the selection of more successful drugs, but only after a threshold when sufficient uncertainty has been resolved. This paper was accepted by Jayashankar Swaminathan, operations management. Supplemental Material: Data and the online appendix are available at https://doi.org/10.1287/mnsc.2022.4642 .Keywords
This publication has 59 references indexed in Scilit:
- A call for transparent reporting to optimize the predictive value of preclinical researchNature, 2012
- Managing Technology Selection and Development Risk in Competitive EnvironmentsProduction and Operations Management, 2011
- Innovation objectives, knowledge sources, and the benefits of breadthStrategic Management Journal, 2009
- Up or Out—or Stay Put? Product Positioning in an Evolving Technology EnvironmentProduction and Operations Management, 2005
- Value of novelty?Nature Reviews Drug Discovery, 2002
- Asset accumulation, interdependence and technological change: evidence from pharmaceutical drug discoveryStrategic Management Journal, 2002
- To be different, or to be the same? It’s a question (and theory) of strategic balanceStrategic Management Journal, 1999
- Organizational Evolution in the Interorganizational Environment: Incentives and Constraints on International Expansion StrategyAdministrative Science Quarterly, 1998
- Racing To Invest? The Dynamics of Competition in Ethical Drug DiscoveryJournal of Economics & Management Strategy, 1994
- Issues in Assessing the Contribution of Research and Development to Productivity GrowthThe Bell Journal of Economics, 1979